[go: up one dir, main page]

AR006790A1 - Forma de dosificacion solida que comprende cis-4-amino-5-cloro-n-[1-[3-(4-luorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida independientedel ph, de liberacion inmediata, una tableta del mismo, un proceso para su preparacion y un producto del mismo - Google Patents

Forma de dosificacion solida que comprende cis-4-amino-5-cloro-n-[1-[3-(4-luorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida independientedel ph, de liberacion inmediata, una tableta del mismo, un proceso para su preparacion y un producto del mismo

Info

Publication number
AR006790A1
AR006790A1 ARP970101627A ARP970101627A AR006790A1 AR 006790 A1 AR006790 A1 AR 006790A1 AR P970101627 A ARP970101627 A AR P970101627A AR P970101627 A ARP970101627 A AR P970101627A AR 006790 A1 AR006790 A1 AR 006790A1
Authority
AR
Argentina
Prior art keywords
same
dosage form
cis
amino
solid dosage
Prior art date
Application number
ARP970101627A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR006790A1 publication Critical patent/AR006790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a formas de dosificación oral de algunas sales particulares de cisaprida, cis-4-amino-5-cloro-N-[1-[3-(4-fluorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida más en particular cisaprida-(L)-tartrato, cisaprida-(D)-tartrat o,cisaprida-sulfato, o cisaprida citrato, lo que evitala interacción de alimentos, y lo que permite la comedicación de agentes que incrementan el pH del estómago. Se relaciona en particular con formas dedosificación oral sólidas adecuadas pra ladisolución rápida. Además se refiere a tabletas que pueden ser preparadas mediante la compresión directa,al proceso para la preparación de una forma de dosificación sólida y a un producto que comprende dicha forma de dosificaciónsólida
ARP970101627A 1996-04-23 1997-04-22 Forma de dosificacion solida que comprende cis-4-amino-5-cloro-n-[1-[3-(4-luorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida independientedel ph, de liberacion inmediata, una tableta del mismo, un proceso para su preparacion y un producto del mismo AR006790A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23

Publications (1)

Publication Number Publication Date
AR006790A1 true AR006790A1 (es) 1999-09-29

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101627A AR006790A1 (es) 1996-04-23 1997-04-22 Forma de dosificacion solida que comprende cis-4-amino-5-cloro-n-[1-[3-(4-luorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida independientedel ph, de liberacion inmediata, una tableta del mismo, un proceso para su preparacion y un producto del mismo

Country Status (23)

Country Link
US (1) US6030988A (es)
JP (1) JPH10510559A (es)
KR (1) KR100204115B1 (es)
CN (1) CN1216467A (es)
AR (1) AR006790A1 (es)
AT (1) ATE220543T1 (es)
AU (1) AU720582B2 (es)
BG (1) BG102812A (es)
BR (1) BR9708585A (es)
CA (1) CA2201264C (es)
CZ (1) CZ332598A3 (es)
DE (1) DE69713948D1 (es)
EA (1) EA000804B1 (es)
EE (1) EE03552B1 (es)
ID (1) ID16666A (es)
IL (1) IL125979A0 (es)
NO (1) NO984016L (es)
NZ (1) NZ331705A (es)
PL (1) PL328917A1 (es)
SK (1) SK144698A3 (es)
TR (1) TR199802139T2 (es)
WO (1) WO1997039744A1 (es)
ZA (1) ZA973449B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
WO2001028559A1 (en) 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
MX2021000403A (es) 2018-07-12 2021-03-25 Sichuan Haisco Pharmaceutical Co Ltd Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08502031A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
EP0707492A1 (en) * 1993-07-06 1996-04-24 Merck & Co. Inc. H 2? antagonist-gastrointestinal motility agent combinations
EP0670160B1 (en) * 1994-03-01 1999-07-14 Gerhard Dr. Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
ID16666A (id) 1997-10-30
BR9708585A (pt) 1999-08-03
NO984016D0 (no) 1998-09-01
IL125979A0 (en) 1999-04-11
WO1997039744A1 (en) 1997-10-30
US6030988A (en) 2000-02-29
EE9800269A (et) 1999-02-15
CA2201264C (en) 1999-08-10
CN1216467A (zh) 1999-05-12
EA199800861A1 (ru) 1999-02-25
EA000804B1 (ru) 2000-04-24
EE03552B1 (et) 2001-12-17
ZA973449B (en) 1998-10-22
KR970069038A (ko) 1997-11-07
ATE220543T1 (de) 2002-08-15
JPH10510559A (ja) 1998-10-13
AU2290497A (en) 1997-11-12
NO984016L (no) 1998-12-23
NZ331705A (en) 1999-11-29
CZ332598A3 (cs) 1999-01-13
CA2201264A1 (en) 1997-10-23
DE69713948D1 (de) 2002-08-22
SK144698A3 (en) 1999-05-07
BG102812A (en) 1999-05-31
AU720582B2 (en) 2000-06-08
PL328917A1 (en) 1999-03-01
KR100204115B1 (ko) 1999-06-15
TR199802139T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
AR006790A1 (es) Forma de dosificacion solida que comprende cis-4-amino-5-cloro-n-[1-[3-(4-luorfenoxi)propil]-3-metoxi-4-piperidinil]-2-metoxibenzamida independientedel ph, de liberacion inmediata, una tableta del mismo, un proceso para su preparacion y un producto del mismo
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR008002A1 (es) Formulaciones de unidades múltiples de tramadol y procedimiento para prepararlas.
AR045353A1 (es) Forma de dosificacion a prueba de abuso
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
MXPA04005011A (es) CáPSULA CON RáPIDA SOLUBILIZACION Y LIBERACION DE CONTENIDO.
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
AR018829A1 (es) Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos
PT833618E (pt) Forma farmaceutica solida para utilizacao oral
HUP0301685A3 (en) New aporphine esters and their use in therapy, process for their preparation and pharmaceutical compositions containing them
MXPA04004974A (es) Composiciones farmaceuticas que comprenden metformina y glibenclamida para tratamiento de diabetes mellitus tipo ii.
NO20031622D0 (no) Medisinske blandinger som raskt desintegrerer i munnhulen og fremgangsmåtefor fremstilling av samme
HUP0302770A3 (en) Tripeptidyl peptidase inhibitors, process for their preparation and pharmaceutical compositions containing them
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ECSP078014A (es) Regimen de dosificacion para prasugrel
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
DE60103276D1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem
ES2478565T3 (es) Composiciones y sus usos
DE60211916D1 (de) Synergistische füllzusammensetzung
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
DE60135441D1 (de) Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
ECSP055895A (es) Producto farmacéutico de alergeno

Legal Events

Date Code Title Description
FB Suspension of granting procedure